As a disease entity, oesophageal cancer principally com prises two epidemiologically and pathologically distinct diseases that share an anatomical site: oesophageal squa mous cell carcinoma (OSCC) and oesophageal adeno carcinoma (OAC) (TABLE 1). OSCC and OAC have divergent risk factors and incidence trends. OSCC is the most common type worldwide, but its incidence is declining in most parts of the world. By contrast, OAC incidence rates have risen sharply in developed countries over the past four decades [1] [2] [3] . Biologically, OSCC shares many characteristics with squamous cell carcinoma of the head and neck, whereas OAC resembles chromo somally unstable gastric adenocarcinoma in its genetic makeup 4 . Dysplastic precursor lesions can be detected for both OSCC and OAC using endoscopy and non invasive screening methods, but routine screening is not currently recommended in lowrisk areas or for lowrisk individuals 5 . Local ablative treatment of these dysplastic lesions results in excellent longterm outcomes, with out the requirement for extensive oesophageal resec tion or intensive oncological treatment, and some early cancers may also be treated successfully with endoscopic resection 6, 7 . Patients with locally advanced cancer fre quently develop recurrent disease, although the use of chemotherapy or chemoradiotherapy as an adjunct to surgery has improved the prognosis 6 . Of note, defin itive chemoradiotherapy (that is, chemoradiotherapy without subsequent oesophagectomy) is only a standard of care for OSCC. In advanced or metastatic oesopha geal cancer, combination chemotherapy regimens extend survival. However, the current median survival time is still <1 year [8] [9] [10] [11] . To improve overall survival, novel therapies tailored to the molecular composition of the tumour are urgently required. Finally, as oesophageal cancer treated with curative or palliative intent results in a substantial symptom burden and changes in quality of life (QOL), paying attention to symptom control and other patientreported outcomes is important 12, 13 . In this Primer, we provide an uptodate overview of findings regarding the epidemiology, pathogenesis and treatment of oesophageal cancer, including endoscopic, surgical and medical oncology approaches, as well as the effect of the disease on the QOL of patients, and emerg ing data on screening and chemoprevention. As OSCC and OAC are associated with divergent histology and biology, anatomical sites of disease and aetiological factors, we discuss their epidemiology, pathogenesis and molecular biology separately below (TABLE 1) .
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Epidemiology
Oesophageal cancer is the sixth most common cause of cancerassociated death globally. In 2012, there were an estimated 456,000 diagnoses of oesophageal cancer worldwide. Of the total number of oesophageal cancers the past four decades; the average annual increase has ranged from 3.5% (95% CI: 3.3-3.7) per year in Scotland to 8.1% (95% CI: 6.4-10.0) per year in Hawaii 2, 20 .
Mechanisms/pathophysiology OSCC Risk factors. OSCC develops from the squamous epithe lial cells that make up the inner lining of the oesophagus. Recurrent chemical or physical insults to the oesopha geal mucosa increase the risk of OSCC. In nonendemic areas, OSCC is predominantly associated with tobacco smoking and the overconsumption of alcohol. Tobacco smoke contains carcinogens, such as polycyclic hydro carbons, nitrosamines and acetaldehyde, and active smoking is associated with a 5fold to 9fold increase in the overall risk of OSCC 21 , but the relative risk is lower in endemic areas (for example, the risk is increased just 1.3fold for smokers relative to nonsmokers in Linxian, China 22 ). The deleterious effects of alcohol on the oesophageal mucosa are mediated by acetaldehyde, secondary to oxidation by the oral microbiota and sali vary products. Pharmacogenetic differences in alcohol metabolism in Asian populations increase acetaldehyde exposure in this population 23 . Smoking and alcohol synergize to increase the risk of OSCC 24 . A low intake of fruit and vegetables is also associ ated with increased OSCC risk, as are specific regional marginal micronutrient deficiencies (for example, defici encies in vitamin A and vitamin E) [25] [26] [27] . Many of these risk factors for OSCC are associated with lower socio economic status, and accordingly, OSCC is more common in economically deprived groups and regions 28 . Recurrent thermal injury due to the ingestion of high temperature beverages such as tea may be contributory to regional variation in OSCC incidence in, for example, northern Iran 29 . Finally, human papillomavirus (HPV) infection has been suggested to be associated with OSCC. However, data from The Cancer Genome Atlas (TCGA) have demonstrated that OSCC has a molecular profile that is consistent with HPVnegative squamous cell carci noma, suggesting that HPVassociated OSCC may reflect the heterogeneity of HPV prevalence globally rather than reflecting a causative effect 4, 30 . The role of inherited genetic variants on OSCC cancer risk is modest apart from in rare familial cases. Tylosis is an autosomal dominant disorder caused by a germline mutation in RHBDF2 (which encodes rhomboid 5 homo logue 2, a protein that is also known as iRHOM2). The disorder is associated with palmar and plantar hyper keratosis, and with a 90% cumulative risk of developing OSCC by 70 years of age 31 . Largescale genomewide association studies (GWAS) in China have identified susceptibility loci with an odds ratio (OR) of 1.3-1.4 for OSCC at the following chromosomal locations: 10q23 (which encodes phospholipase Cε1, an enzyme associ ated with growth, differentiation and apoptosis); 5q31.2 (which encodes transmembrane protein 173, a protein associated with the type I interferon response to microbial infection); 17p13.1 (which encodes sodium/potassium dependent ATPase sub unit β2; this gene is local ized in close proximity to TP53 (which encodes p53)); and, specifi cally in highrisk areas, the HLA class II region (6p21.32) [32] [33] [34] . Variability in genes involved in detoxifi cation processes may also modify environ mental influ ences on OSCC susceptibil ity. For example, functional variants in the enzymes alcohol dehydrogenase 1B and aldehyde dehydro genase 2 syner gize with lifestyle factors to increase OSCC risk in the Japanese population 35 .
Pathogenesis and molecular characterization. OSCC develops from basal cell hyperplasia and dysplasia (low to high grade) to carcinoma in situ (Tis) (FIG. 2) . The molecular progression from dysplasia to OSCC, which is invasive, has not been well studied, but dysregulation of TP53 and the genes that encode other cell cycle regu lators (such as cyclindependent kinase inhibitor 2A (CDKN2A) and retinoblastomaassociated protein (RB; encoded by RB1)) is a prominent character istic of OSCC; these changes can already be detected in pre cursor lesions 36 . Abnormal p53 expression has been demonstrated in oesophageal tissue adjacent to dys plasia or OSCC, and increased levels of CDKN2A and RB have been associated with a stepwise progression from inflammation to cancer in oesophageal lesions 37, 38 . Differentiating between normal and dysplastic tissue for accurate risk stratification is challenging, but the evalu ation of genes that are differentially expressed in normal oesophageal mucosa and OSCC has identified two candi date biomarkers that could aid in the future diagnosis of dysplasia or invasive OSCC. Indeed, the expression of TNFAIP3 (which encodes tumour necrosis factor induced protein 3) and CHN (which encodes chimerin 1) increases during the transition from normal tissue to dysplasia to carcinoma 39 . Several recent largescale sequencing and multi platform studies have evaluated the mutational, tran scriptomic and epigenetic profiles of OSCC. According to TCGA data, point mutations and small insertions or deletions (indels) were most commonly detected in TP53, KMT2D (which encodes lysine methyltrans ferase 2D; also known as MLL2) and NFE2L2 (which encodes nuclear factor erythroid 2like 2), whereas amplifications were frequently identified in SOX2, TP63 and FGFR1 (which encode SRYbox 2, tumour pro tein 63 and fibroblast growth factor receptor 1, respec tively) (TABLE 2) . These data confirm the results of several previous studies 4, [40] [41] [42] . Dysregulated pathways that are of therapeutic interest in OSCC include cell cycle regu lation, receptor tyrosine kinase signalling, chroma tin remodelling and embryonic pathways such as the Hippo signalling pathway (via the amplification of YAP1 (which encodes Yesassociated protein 1), or deletion of VGLL4 (which encodes vestigial like family member 4) or ATG7 (which encodes autophagyrelated gene 7)). According to TCGA, CDKN2A was inactivated in 76% of tumours, and amplifi cations of CCND1 (which encodes cyclin D1) were present in 57%, confirming other stud ies 40, 41 . The epidermal growth factor receptor (EGFR) signalling pathway was activated via mutation or amplifi cation in 19% of tumours, and phosphoino sitide 3kinase catalytic subunitα (PIK3CA) was activated in 13% of tumours. Each of these pathways has been success fully targeted using tyrosine kinase inhibitors that are currently approved for use in other types of tumour.
OAC

Risk factors.
OAC arises primarily from Barrett oesoph agus (a preneoplastic tissue in which the squamous oesophageal epithelium is replaced by a columnar intestinaltype mucosa). Its predominant localization is the lower oesophagus, and the tumour has a glandular structure. Gastrooesophageal reflux of acid and/or bile is the most important risk factor for OAC. In a population based case-control study and a metaanalysis, gastro oesophageal reflux disease is associated with an OR of 12.00 (95% CI: 7.64-18.70) for Barrett oesophagus and 4.64 (95% CI: 3.28-6.57) for OAC 43, 44 . 43, 45, 46 . In addition, reflux and obesity can have a synergistic effect. Obesity is associated with increased intraabdominal pressure, which can increase reflux, and the obesity related meta bolic syndrome is also a risk factor for Barrett oesophagus independent of reflux symptoms 47 .
Tobacco smoking is a moderately strong risk factor for OAC, but its association with Barrett oesophagus is less clear, and alcohol consumption does not seem to substantially increase the risk of Barrett oesophagus and OAC 43, 48, 49 . Other risk factors for OAC include male sex (there is a maletofemale ratio of 7:1), high red meat intake (OR: 1.91 (95% CI: 1.07-3.38) for the highest ver sus the lowest tertile of red meat intake), and low fruit and vegetable intake (OR: 0. 86 per portion of fruit or vegetables per day) 43, 50, 51 . By con trast, Helicobacter pylori infection demonstrates an inverse association with Barrett oesophagus and OAC risk, and decreasing population seropositivity for H. pylori owing to improved socioeconomic conditions might contribute to the rising rates of OAC 52, 53 . Genetics contributes up to onethird of the risk for sporadic Barrett oesophagus and OAC develop ment, and approximately 7% of cases of Barrett oesopha gus and OAC may be familial [54] [55] [56] . GWAS have identified susceptibility loci in genes that encode proteins involved in the embryonic development of the oesophagus (for example, FOXF1 and BARX1 (which encode fork head box F1 and BARX homeobox 1, respectively)), in the host immune response (that is, the HLA locus 16q24.1), and in cellu lar proliferation and transformation (for example, CRTC1 (which encodes CREBregulated transcription coactiv ator 1 and is found on 19p13)) 57 . The importance of genes that are actively transcribed in the embryonic period in the development of OAC is empha sized by the results of a large meta analysis of all available GWAS on Barrett oesophagus and OAC (including 6,167 patients with Barrett oesopha gus and 4,112 patients with OAC); this metaanalysis identified several new risk loci, including ABCC5 (which encodes ATPbinding cassette subfamily C member 5; OR: 1.17 (95% CI: 1.11-1.24) for OAC only), which is also associated with oesophageal development 58 . Finally, germline variation in inflam mation response genes, such as MGST1 or FOXP1 (which encode microsomal glutathione Stransferase 1 and forkhead box P1, respectively), may affect the genet ically determined host response to inflammation, and thus also influence individual Barrett oesophagus and OAC risk 59, 60 .
Progression from Barrett oesophagus to OAC. Typically, damage to the oesophageal mucosa due to acid or bile exposure is the consequence of the formation of reactive oxygen species and nitric oxide, which cause DNA damage and a characteristic mutational profile with A>C transversions (FIG. 2) . This basetransversion profile is common in Barrett oesophagus and OAC, lending fur ther support to the hypothesis that these DNAdamaging factors are causally acting early in disease patho genesis [61] [62] [63] . Hence, it is generally agreed that Barrett oesophagus occurs as an adaptive response to recurrent injury to the squamous mucosa 64, 65 . In a minority of patients (0.12-0.60% annually), the metaplastic mucosa associated with Barrett oesophagus progresses through lowgrade and then highgrade dysplasia to invasive OAC, and much effort is ongoing to understand the triggers and pathways that underlie progression, so that highrisk patients can be identified more accurately than they are at present [66] [67] [68] . Figure 2 | The pathogenesis of OSCC and OAC. The oesophageal mucosa is exposed to repeated insults, which result in changes to the squamous oesophageal mucosa. Molecular changes also accumulate, and this ultimately leads to a malignant phenotype. In oesophageal squamous cell carcinoma (OSCC), squamous hyperplasia precedes low-grade and high-grade squamous dysplasia, which then develops into invasive cancer. In oesophageal adenocarcinoma (OAC), a metaplastic epithelium (Barrett oesophagus) is transformed through low-grade and high-grade dysplasia to invasive cancer. CDKN2A, cyclin-dependent kinase inhibitor 2A; RB, retinoblastoma-associated protein.
Barrett oesophagus is a preneoplastic lesion that fre quently contains somatic genetic alterations that pre dispose to carcinogenesis. Two mechanisms of OAC generation from Barrett oesophagus have been pro posed. The first mechanism involves the stepwise loss of tumour suppressor genes such as CDKN2A and TP53, and also involves mutations in SMAD4 and the disrup tion of chromatinmodifying enzymes, but without an acute genomedoubling event. Indeed, mutations in TP53 and SMAD4 seem to occur early in tumour develop ment. This observation might be helpful when seeking to identify patients who are at risk of progression to OAC 69 . The second mechanism involves largescale chromo somal instability that is associated with aneuploidy follow ing the loss of p53 regulation 70 . The acquisition of loss of heterozygosity of 17p (which contains TP53) in Barrett oesophagus has been associated with the development of aneuploidy and with an increased poten tial for malignant progression 71, 72 . A paired sequencing study of Barrett oesophagus and OAC samples from 25 patients demonstrated that a genome doubling event in TP53mutant cells commonly precedes OAC develop ment 70 . Furthermore, tumours that have undergone a genomedoubling event have distinct character istics, including an increased number of focal genomic amplifications.
Other mechanisms -for example, chromothrip sis and kataegis -may lead to chromosomal instability and accelerate the progression from Barrett oesophagus to invasive OAC. These mechanisms can explain the lack of copynumber alterations in Barrett oesopha gus compared with invasive OAC, despite similar mutational signatures 73 . . ‡ Presentation of upregulation (↑) or downregulation (↓) of the specified pathway in tumours harbouring the specified mutation.
Clonal diversity is as common in Barrett oesophagus as in OAC, and greater clonal diversity is associated with an increased risk of progression from Barrett oesophagus to invasive OAC [72] [73] [74] [75] . This implies that sampling Barrett oesophagus requires a wide sampling field to improve the accuracy of risk stratification; as taking multiple biopsies increases the patient's risk of complications -such as perforation or haemorrhage -noninvasive strategies may be preferred in the future 76 . Epigenetic modification is another factor in OAC development. The levels of DNA methylation in both Barrett oesophagus and OAC are high relative to the levels found in normal oesophageal mucosa, although the levels are heterogeneous 77 . For example, hypermethyl ation of the promoter of CDKN2A is frequent and associ ated with neoplastic progression in Barrett oesophagus, and, together with the loss of 9p21, it may lead to the inactivation of CDK2NA 4, 78, 79 .
Genetics of invasive OAC. OAC has a high point mutation burden (9.9 mutations per Mb (range: 7.1-25.2 per Mb)) relative to other cancers, but the burden is lower than that of lung cancer and melanoma 63, 80 . However, although point mutations are abundant particu larly in tumour suppressor genes, such as TP53, CDK2NA and ARID1A (which encodes ATrich inter action domain 1A), structural alterations dominate the OAC landscape 4, 63, 69, 80, 81 (TABLE 2) . Copynumber alterations (amplifications and deletions) are common; amplifications of potential therapeutic relevance are fre quently found in the genes that encode receptor tyrosine kinases (that is, HER2 (which encodes human epidermal growth factor receptor 2; also known as ERBB2), EGFR, KRAS and FGFR2), cell cycle regulators (for example, CCND1 and CDK6 (which encodes cyclindependent kinase 6) and transcription factors (for example, MYC, GATA4 (which encodes GATAbinding protein 4) and GATA6) 4, 63, 82, 83 . Coamplification (that is, the amplifica tion of more than one gene in the same tumour) of recep tor tyrosine kinases is common (specifically for HER2 and EGFR), and is probably associated with both de novo and acquired resistance to targeted therapy, which pose a challenge for drug selection and development [84] [85] [86] . The gross chromosomal instability associated with OAC is shared with chromosomally unstable gastric cancer 4 . The clonal heterogeneity and coamplification profiles of OAC make targeted therapies a challenge. However, an alternative classification system based on molecular subgroups might enable the identification of different avenues for therapeutic intervention. Following wholegenome sequencing of 129 OAC samples as part of the International Cancer Genome Consortium, three subgroups were identified: one subgroup showed changes characteristic of defective homologous recombination repair, another showed a T>G mutation pattern associated with a high mutational load, and a third group had a C>A or C>T mutation pattern that was consistent with an age ing imprint 84 . Effective treatments for the DNA damage repairdeficient subtype might potentially include inhib itors of poly(ADPribose) polymerase (PARP) and the serine/threonineprotein kinase ATR, or platinumbased chemotherapy, whereas the subgroup with a high muta tional burden might benefit from immuno oncology thera pies. However, further functional and clinical validation of these subgroups is required.
Diagnosis, screening and prevention
As the clinical symptoms and diagnosis of OAC and OSCC are similar, we discuss them together.
Diagnosis of oesophageal cancer
Owing to the muscular and expansive nature of the oesophagus, the symptoms resulting from an obstruct ing lesion or stricture only become apparent when the tumour has reached a relatively locally advanced or even metastatic stage. Warning symptoms include dif ficulty swallowing (dysphagia) or pain when swallow ing (odyno phagia), involuntary and progressive weight loss, and hoarseness or cough; cough can signify laryn geal nerve involvement or aspiration. Occasionally, patients may vomit blood or pass melaena (dark stool produced as a consequence of internal bleeding in the upper gastro intestinal tract). Fatigue may occur due to anaemia resulting from chronic, occult bleeding or a chronic disease burden. Clinical examination should focus on the assessment of performance status and the evaluation of clinically apparent metastatic disease (for example, evalu ation of the supraclavicular lymph nodes and hepatomegaly (that is, an enlarged liver)).
Endoscopy is the gold standard for the detection and diagnosis of oesophageal cancer, as the clinical examin ation is often unremarkable even with locally advanced disease 87 . Endoscopy can be improved by using Lugol's iodine dye (chromoendoscopy) to identify early OSCC or by using narrowband imaging, in which light of speci fic wavelengths is used to improve the resolution of the sur face mucosa (FIG. 3) . Tumour characteristics that should be documented at endoscopy include the exact site of the tumour (relative to the gastro oesophageal junc tion, extension into the stomach and distance from the teeth), the length of the lesion, circumferential involve ment and the presence of obstruction 7 . Any adjacent pre malignant lesions (that is, squamous cell dysplasia or Barrett oesophagus) should be documented and meas ured. As the mucosa can be friable owing to ulceration or necrosis, it is recommended that a minimum of six biopsies are analysed for histological confirmation 88 . Histology should be classified according to the WHO criteria, and the histological subtype (that is, adeno carcinoma, squamous cell carcinoma, undiffer entiated cancer or rare cancer) and grade should be documented 7, 89 . If the histological subtype is difficult to determine, histochemical or immunohistochemical stain ing may help. Markers that may distinguish OAC from OSCC include periodic acidSchiff staining (to identify mucussecreting cells), cyto keratin 7 and cytokeratin 20 for OAC, whereas cytokeratin 5, cyto keratin 6 and p63 are more frequent in OSCC 90 . The identifi cation of rare cancers that can affect the oesophagus (such as small cell carcinoma, neuro endocrine tumours, lymphoma, gastro intestinal stromal tumours and melanoma) is essential as they may require specific treatment. HER2 staining should be performed in patients with advanced tumours who are not suitable for curative therapy and in whom trastuzumab (an antiHER2 antibody) might be a treatment option 6, 7 .
Staging of oesophageal cancer
As oesophagectomy is associated with considerable mor bidity and changes in postoperative QOL, the careful selection of patients who meet the criteria for resection surgery (that is, patients who do not have metastatic cancer and are fit for surgery) is essential to minimize the risk of futile surgery in patients with incurable dis ease. Diagnostic endoscopic mucosal dissection or resec tion may be an alternative in very earlystage tumours (mainly in Tis-T1a tumours).
The staging of oesophageal cancer should be per formed according to the tumour-node-metastasis (TNM) classification (FIG. 4) published by the current American Joint Council on Cancer 91 . Three classification systems are available depending on the mode of staging: namely, clinical or radiological staging (c stage), pathological staging (p stage) determined after primary surgery or endoscopy for localized disease or pathological staging after neoadjuvant therapy (yp stage).
To identify the T stage of the primary tumour, endo scopic ultrasonography is more sensitive and specific than is CT; endoscopic ultrasonography has a sensitivity and specificity of 81−92% and 94−97%, respectively 92 . In addi tion, endoscopic ultrasonography enables the sampling of suspicious lymph nodes to assess the N stage 92, 93 (FIG. 4) .
All surgical candidates should undergo PET or PET-CT, if available, to identify occult metastases (M stage); metasta ses are detected in approximately 15% of patients who are considered to be candidates for surgery on the basis of endoscopic ultrasonography and CT 94, 95 . Staging laparoscopy, which can be performed in patients with ≥cT3 or cN + tumours at the gastrooesophageal junction that infiltrate the cardia, may identify a similar proportion of patients with occult peritoneal disease 95, 96 . Patients with tumours at or above the carina of the trachea may undergo bronchoscopy to assess suspicious tracheal involve ment, whereas those with OSCC in the context of tobacco and alcohol use should be evaluated for synchronous primary tumours of the aerodigestive tract 6, 7 .
Metabolic imaging in OAC
Changes in the degree of 18 Ffluorodeoxyglucose (FDG) radionucleotide uptake, as imaged by FDGPET, are informative in patients with OAC who are treated with neoadjuvant chemotherapy. Patients who do not achieve a ≥35% reduction in the standardized FDG uptake value following 2 weeks of platinumfluoropyrimidine chemo therapy have worse overall survival than good metabolic responders 97, 98 . Discontinuing chemotherapy following a poor response based on FDGPET imaging does not result in inferior survival compared with historical con trols 99 . The addition of radiotherapy to poor metabolic responders may improve pathological response rates and resection rates, but not survival 99, 100 . The CALGB80803 study has reported that improved pathological complete response (pCR) rates (defined as the absence of a tumour in the surgical resection specimen) after switching to an alternative chemotherapy regimen during chemo radiotherapy in FDGPET determined poor metabolic responders. The pCR rate in poor metabolic responders who crossed over to a different chemotherapy was 18%, which -although lower than the pCR rate in patients who initially responded to induction chemotherapy and did not switch (26%) -is better than expected (the pri mary end point was a pCR of 15%); the survival results are not yet known 101 . These findings suggest that meta bolic imaging can be used to identify patients with OAC who have a poor prognosis. Further investigation of PETdirected therapy is warranted.
Screening for oesophageal cancer
In Europe and North America, the majority of patients with oesophageal cancer present with locally advanced or metastatic disease that is not amenable to curative therapy. In the United Kingdom, 70-80% of patients are diagnosed with either lymph node or distant metasta ses 15 . However, although both OSCC and OAC have recognized noninvasive precursor lesions that may be treated endoscopically using ablation or resection, the low population prevalence of oesophageal cancer in Nature Reviews | Disease Primers a c b d Figure 3 | An endoscopic image of early OSCC. a | White-light endoscopy shows an area of mucosal erythema (indicated by the arrowhead) and an additional ill-defined subtle area of reddened mucosa with a white edge (arrow). b | Narrow-band imaging (NBI) of the same endoscopic field shows two brown areas suspicious for early cancer (arrows). c | NBI magnification shows dilated intrapapillary capillary loops that are consistent with mucosal cancer (arrows). d | Lugol's iodine chromoendoscopy enables the precise demarcation of the two lesions (the yellow arrowheads indicate the distal lesion; the white arrowheads indicate the proximal lesion), which appear as pale mucosa (unstained lesion) surrounded by normal mucosa that is avidly stained brown by 2.5% iodine solution. Pathological analysis of the endoscopic resection specimen showed intramucosal squamous cell carcinoma with invasion of the muscularis mucosae (tumour-node-metastasis (TNM) stage pT1a, M3). OSCC, oesophageal squamous cell carcinoma. Images courtesy of M. di Pietro, University of Cambridge, Cambridge, UK.
the West is a barrier to the implementation of screen ing programmes 102 . The current American College of Gastroenterology and British Society of Gastroenterology guidelines suggest screening in patients who have a history of gastro oesophageal reflux lasting >5 years and have multiple (≥2-3) other risk factors, including male sex, Caucasian race, central obesity and current or past history of smoking. The threshold for multiple risk factors may be adjusted in the presence of a pos itive family history. Practices in other countries depend on countryspecific guidelines 5, 103 . There are no current screening guidelines for OSCC, although studies have shown that oneoff endoscopic screening using Lugol's chromoendoscopy in highrisk areas in China decreased OSCC incidence and OSCCrelated mortality 19 . Another impediment to introducing screening is the fact that the diagnostic modality -endoscopy -is inva sive and expensive, and therefore alternative, less invasive approaches are of interest and would enable the screen ing of a broader population. Transnasal endo scopy is less invasive than standard endoscopy, does not require sedation, and demonstrates equivalent sensitivity and specificity for the detection of Barrett oesophagus when tested in atrisk populations 104, 105 . However, transnasal endoscopy does require investment in equipment as well as skilled operators, and further largescale studies in the relevant populations are needed. Other methods of screening include capsule endoscopy (the ingestion of a small video camera) and cytology retrieval devices, such as balloons and sponges. However, capsule endoscopy has a relatively low sensitivity and specificity (73% and 78%, respectively) for the detection of Barrett oesopha gus, and it is not recommended for screening by current guidelines 103, 106 . The Cytosponge is a non endoscopic cellcollection device comprising a sponge compressed within a gelatin capsule that expands upon swallowing and can be retrieved from the oesophagus by pulling a string 107 . Immunohistochemistry for trefoil factor 3 (which is a marker of columnar epithelium) on cyto logical specimens obtained by Cytosponge yields a sensitivity (including inadequate samples in which the Cytosponge had not reached the stomach) and specifi city for the diagnosis of Barrett oesophagus of 79.9% (95% CI: 76.4-83.0%) and 92.4% (95% CI: 89.5-94.7%), respectively, and the sensitivity increases markedly in patients who have long segments of Barrett oesophagus (≥3 cm). The sensitivity approaches 90% (89.7% (95% CI: 82.3-94.8%)) with a second swallow 108 . The use of the Cytosponge to screen for Barrett oesophagus is now being evaluated in a large primary care trial that has a cluster randomized design and involves 9,000 patients who are receiving an acidsuppressant prescription for reflux symptoms 109 . However, further risk stratification biomarkers are required as only a small proportion of patients with Barrett oesophagus will ultimately develop OAC, and surveillance endoscopy of all patients with Barrett oesophagus would have a substantial logisti cal burden [110] [111] [112] [113] . Aberrant p53 expression (both over expression and loss) may be a more accurate predictor of progression than the presence of lowgrade dysplasia, which is prone to interobserver and intraobserver vari ability 114, 115 . The expression of p53 can be evaluated as a secondtier test on the same Cytosponge samples used for trefoil factor 3 staining. A panel of biomarkers may enable those patients who are at a low risk of progression to be spared an endoscopy 69, 76 . Nature Reviews | Disease Primers categories. T refers to the size of the primary tumour and whether it invades the nascent tissue as shown. N refers to lymph node involvement: N0 describes no regional lymph node metastasis; N1 describes regional lymph node metastases involving one or two nodes; N2 describes regional lymph node metastases involving from three to six nodes; and N3 describes regional lymph node metastases involving seven or more nodes. M refers to distant metastasis and is categorized as M0 (no distant metastasis) or M1 (distant metastasis). HGD, high-grade dysplasia; Tis, cancer in situ. Adapted with permission from REF. 247 , Elsevier.
Oesophageal cancer prevention
The primary prevention of oesophageal cancer is based on the avoidance of risk factors, and includes tobacco avoidance and the moderation of alcohol intake for the prevention of OSCC, the maintenance of a healthy weight for the prevention of OAC, and increasing fresh fruit and vegetable intake with a reduction in red meat consumption for both. For patients with Barrett oesophagus, secondary prevention could potentially include pharmaco logical therapy with proton pump inhibitors (PPIs) or NSAIDs, locally ablative therapies to remove neo plastic pre cursor lesions and antireflux surgery 116 . PPIs are frequently used in the setting of chronic reflux, and some cohort studies and metaanalyses suggest that patients with Barrett oesophagus who are treated with PPIs have lower rates of dysplasia and OAC than do those who are not treated with PPIs [117] [118] [119] . Although bias caused by the sever ity of reflux is a potential confounder of these studies, it may be reasonable to discuss PPI treatment even with patients who have asymptomatic Barrett oesopha gus. The use of NSAIDs including aspirin has been associ ated with reduced cancer risk in several cancer types, including oesophageal cancer [120] [121] [122] . However, NSAIDs are associated with nontrivial toxicities. A higher grade of evidence than currently available is required to institute an NSAIDbased chemo prevention strategy in Barrett oesophagus, and the ongoing phase III ran domized AspECT trial 123 might be informative regarding this approach.
Preventing the progression of dysplastic Barrett oesophagus to OAC is now achievable for many patients using ablative therapies. Patients who have Barrett oesophagus with nodular lesions should undergo endo scopic mucosal resection to determine the grade and extent of the lesion; the presence of dysplasia or carci noma then determines further treatment. For patients with flat, highgrade dysplasia, ablation (using radio frequency ablation or photoablation) provides equiva lent efficacy to surgery with respect to longterm survival and has much less associated morbidity than does oesophagectomy. For patients with lowgrade dysplasia, ablation decreases progression both to highgrade dys plasia and to invasive OAC [124] [125] [126] . Patients often require a combination of endoscopic mucosal resection and abla tion therapy 127, 128 . As patients with Barrett oesophagus without signs of dysplasia have a low risk of progression to OAC, and as there are adverse effects associated with treatment, ablative therapy is not recommended for this patient group 103 . It is also important to note that endo scopic monitoring is still recommended following abla tion therapy owing to the risk of recurrence 103 . In the future, assessment of the molecular status of the tumour may reduce the reliance on a subjective diagnosis of dysplasia to identify patients who need therapy.
Patients with OSCC precursor lesions may also bene fit from endoscopic ablative therapy, but neo plastic progression and strictures after ablation seem to be more common in patients with squamous dysplasia than in those with Barrett oesophagus; strictures may occur in up to 21% of patients with squamous dysplasia who have undergone ablation [129] [130] [131] . In highincidence populations in China, studies of chemopreventive strategies that aimed to replace deficient dietary micro nutrients have demonstrated that increasing βcarotene, vitamin E and selenium intake did not reduce OSCC incidence or OSCCassociated mortality 132 . Finally, as aspirin and other NSAIDs decrease the risk of OSCC 133 , these treatments should be prospectively evaluated in wellcontrolled clinical trials.
Management
The management of oesophageal cancer is dependent on the characteristics of the patient (including fitness) and those of the tumour, mainly the TNM stage. Very earlystage tumours may be suitable for endoscopic resection, whereas locally advanced cancers are treated with chemotherapy, chemoradiotherapy, surgical resec tion or combinations of these. Patients with oesophageal cancers that are not suitable for surgical management are treated with systemic chemotherapy (FIG. 5) .
Endoscopic management
Endoscopic management is an option for very early stage oesophageal cancers that have minimal local involvement (stage T1a (and sometimes T1b)), and an absence of lymph node involvement and metasta sis. Although these types of tumour represent only a small proportion of all tumours, the number has been increasing with the increased use of endoscopy for vari ous indications together with the screening and surveil lance of Barrett oesophagus in individuals who are at risk 134 . Endoscopic treatment is most well established for Barrett oesophagus and OAC; it might also be an option for OSCC, but the literature on this is limited.
When OAC is confined to the mucosa and there are no metastases (stage T1a, N0, M0), local endoscopic treatments with endoscopic mucosal resection or endoscopic submucosal dissection -frequently com bined with radiofrequency ablation -have replaced oesophagectomy as the firstline treatment. These local treatments have been demonstrated to be less invasive, are safer, provide a better QOL and have an equally good longterm prognosis 5, 6, 135 
. Focal endo scopic mucosal resection followed by radio frequency ablation might be recommended before stepwise or complete endoscopic mucosal resection owing to the higher rates of complications (that is, strictures, perfor ation and bleeding) following endoscopic mucosal resec tion, whereas the risk of OAC recurrence is equally low (1.4%) 136 . All endoscopic procedures should be carried out by specialized endoscopists working at wellequipped highvolume centres 5 . For moreadvanced OAC tumour stages (that is, stage T1b, N0, M0), oesophagectomy remains the standard of care because submucosal tumour involvement has a 17-26% risk of lymph node metastasis, with the high est rates for tumours that are poorly differentiated, and show lymphovascular invasion and submucosal invasion >500 μm (REFS 137, 138) . However, for patients with T1b tumours who are not fit enough to undergo surgery or definite chemoradiotherapy (for example, because of advanced age or severe comorbidities), endoscopic ther apy can be attempted if the tumour is associated with good prognostic characteristics (that is, if the tumour shows submucosal level 1 invasion, is welldifferentiated and does not show lymphovascular invasion) 5 .
Surgical management
Procedures. Locally advanced, nonmetastatic OAC and OSCC tumours (stage T1b-T4, N1-N3, M0) fre quently require resection. Several approaches for the resection of oesophageal cancer exist, including vari ations in approach and the extent of lymphadenectomy. For tumours located in or near the gastrooesophageal junction, the resection procedure can consist of an oesophagectomy combined with the resection of the proximal part of the stomach or, alternatively, total gastrectomy combined with resection of the distal oesophagus. A systematic review of 10 cohort studies including 3,356 patients found no difference between these approaches in terms of 5year survival or mor bidity 139 . The two approaches also had similar overall survival rates in a recent cohort study of 4,996 patients from the United States 140 .
Outcomes following transhiatal and transthoracic surgery have been compared in a metaanalysis of 8 stud ies (including 3 randomized controlled trials (RCTs)) involving 1,155 patients; no differences in overall sur vival were observed 141 . A smaller metaanalysis of 6 stud ies (including 647 patients) contradicted this finding in 2016, as a slight survival benefit was noted in the trans thoracic group 142 . The risk of pulmonary complications seems to be higher following the trans thoracic approach than following the transhiatal approach, whereas the longterm healthrelated QOL might not differ much between the two approaches 141, 143 . Minimally invasive oesophagectomy has emerged during the past few years as a feasible and safe procedure for oesophagectomy 144 146, 147 . Studies examining shortterm post operative QOL indicate improvements in selected outcomes follow ing minimally invasive procedures compared with following open surgery, but longterm followup of patientreported outcomes is needed to assess the overall potential of minimally invasive approaches.
The optimal extent of lymphadenectomy in sur gery for oesophageal cancer is a matter of controversy. Several studies have indicated a better overall prog nosis when moreextensive lymphadenectomy is per formed 148 . However, some recent studies have indicated that removing more lymph nodes does not have a sur vival benefit over a standard approach in patients with or without metastasis, especially not in patients who have received neoadjuvant therapy [149] [150] [151] . These findings indicate that a tailored approach regarding the extent of lymphadenectomy is needed in the era of multi modality therapy. Sentinel node biopsy (the assessment of tumour cell presence in the first lymph node to which the cancer cells are most likely to have spread) might be a future alternative for determining the extent of lympha denectomy needed, although the unpredictability with which these tumours spread presents a challenge to this approach 152 . Thus, existing systematic metaanalyses and individ ual studies of predominantly observational design indi cate that the above variations in surgical approaches have a limited difference in terms of survival but might affect postoperative complications, morbidity and health related QOL. Thus far, only very few RCTs have been conducted to compare the surgical approaches, and existing observational studies are heterogeneous and often provide inconsistent results; thus, these findings need to be cautiously interpreted. Surgeon characteristics. Some factors directly related to the surgeon have a strong influence on the longterm prognosis of oesophageal cancer. The annual number of oesophagectomies per surgeon is an important and independent prognostic factor for both shortterm and longterm survival, even after adjustment for the hospi tal annual volume of these procedures [153] [154] [155] . Proficiency gain curves have mainly been established for minimally invasive surgery, but learning curves have also recently been identified for open oesophagectomies 156, 157 . The learning curves are longer for achieving a stable long term survival than for stabilizing shortterm mortal ity 156, 157 . The age of the surgeon might be an independent prognostic factor, even after adjustment for surgeon vol ume and other prognostic factors, and there seems to be an optimal 5year prognosis if the surgeon is 52-56 years of age 158 . Finally, surgery later in the week is also an indepen dent prognostic factor and could be associated with the alertness of the surgeon 159 .
Patient characteristics.
Older age is a prognostic factor for surgery outcome, but its influence has declined with medical specialization in surgery. In fact, the negative affect of age only becomes evident after 80 years of age, and is related to comorbidities rather than age itself [160] [161] [162] . A higher Charlson Comorbidity Index (which assigns a score that is based on the presence and severity of 22 comorbid conditions) and previous heart conditions worsen the prognosis after oesophageal cancer surgery, and comorbidities (such as cardiac or respir atory disease) also negatively influence the longterm health related QOL following oesophagectomy 12, 162 . Ethnicity also has a role; white individuals have lower mortality rates corrected for tumour stage than do individ uals of non white ethnicity, but they are also more likely to undergo surgery and have surgery conducted at highvolume centres 163, 164 . Results from metaanalyses have consist ently shown that having a higher BMI is associated with more postoperative complications but a better overall survival 165, 166 . Tobacco smoking is negatively associated with overall survival and more so for current smokers than previous smokers 167 . Tumour stagespecific sur vival among alcohol drinkers is worse than that of nondrinkers 168 . Finally, among socio economic factors, a longer education is followed by better overall survival independent of other prognostic factors, particularly in early tumour stages and in tumours with a squamous cell carcinoma histology 169 . Further research is needed to confirm and fully understand the role of these factors on prognosis after surgery.
Chemotherapy and chemoradiotherapy
Survival for patients with ≥T2 or N + cancers following surgery alone is poor; the overall survival rate 10 years after surgery even for stage 1b is only 50% 170 . Thus, therapies in addition to surgery are required for these patients (FIG. 5) . Current guidelines recommend adjunc tive treatment comprising neoadjuvant or peri operative chemotherapy, radiotherapy or chemoradiotherapy for patients with ≥T2 OAC and OSCC tumours 6, 7 . Most oesophageal cancers are diagnosed at a locally advanced stage (>T2 and/or N + ); for these patients, the purpose of neoadjuvant and perioperative chemotherapy or chemoradiotherapy is to reduce the primary tumour bulk, increase the likelihood of radical (R0) resection, treat micrometastatic disease and decrease the risk of future systemic recurrence. Neoadjuvant therapy also relieves dysphagia and improves nutritional status in the majority of patients, and it may avoid the require ment for feeding tube placement 171 . By contrast, node negative T2 lesions with lowrisk features (<2 cm and well differentiated) can be considered for oesophagec tomy alone in the case of both OAC and OSCC, or con sidered for definitive chemoradiotherapy in the case of OSCC 6, 7 . Although patients with OSCC or OAC have histori cally been treated using similar paradigms, clear bio logical differences between these two histological subtypes exist 4 . This heterogeneity has implications for responses to radiotherapy, patterns of metastatic spread and the interpretation of trial results. In particu lar, the high sensitivity of OSCC to radiotherapy leads to complete and durable pathological responses in a high proportion of patients (up to 40% of patients are progression free at 2 years) following chemoradio therapy, and in a subgroup of complete responders surgery even becomes unnecessary 6, 7, 172, 173 . In contrast to patients with OSCC, patients with OAC are recom mended to undergo surgical resection even in the set ting of a good clinical response to chemoradiotherapy because the complete histopathological response rate to chemoradiotherapy is lower for OSCC than for OAC, and the rate of microscopicpositive disease at the primary tumour site is higher 6, 7 . In all cases, the multidisciplinary planning of neo adjuvant chemotherapy or chemoradiotherapy and surgery is mandatory, and close attention should be paid to performance and nutritional status, in addition to comorbidities, during preoperative assessment 6, 7 .
Box 1 | Definitions
• Endoscopic mucosal resection: an endoscopic procedure that is used to resect and remove a defined area of the oesophageal mucosa. • Endoscopic submucosal dissection: an endoscopic procedure that is used to dissect and remove a defined mucosal area of the oesophagus, but with wider margins than those used during endoscopic mucosal resection.
• Oesophagectomy: surgical removal of the oesophagus.
• Radiofrequency ablation: an endoscopic procedure that uses heat energy to destroy superficial mucosal lesions of the oesophagus, mainly in patients with Barrett oesophagus.
• Transhiatal surgery: a surgical method for oesophagectomy that uses an abdominal approach combined with neck dissection; thoracotomy or thoracoscopy is not used.
• Transthoracic surgery: a surgical method for oesophagectomy in which thoracotomy or thoracoscopy is used, often in combination with an abdominal approach and sometimes also with neck dissection.
A team of experts from various disciplines should review the patients with respect to staging and likely treatment tolerability, and develop a consensus before starting therapy.
Neoadjuvant and perioperative chemotherapy.
The evidence base for neoadjuvant chemotherapy in the curative treatment of patients with OSCC or OAC is substantial (TABLE 3 ). An evaluation of sur gery alone versus two cycles of neoadjuvant cisplatin and fluorouracil prior to surgery in the OE02 trial 174 showed that patients treated with neoadjuvant chemo therapy had an absolute overall survival benefit of 5.9% at 5 years. The overall survival benefit was not signifi cantly different between OAC and OSCC (5% versus 8%, respectively) 175 . However, in practice, chemoradio therapy -and not chemotherapy -is preferred for patients with OSCC owing to the excellent responses associated with radiotherapy in this population.
For patients with OAC, the addition of epirubicin to cisplatin and capecitabine chemotherapy (ECX) and extending preoperative therapy to four cycles did not improve overall survival in the OE05 study 176 , and there fore doublet chemotherapy is the preferred neo adjuvant treatment. The MAGIC trial and the FNCLCC/FFCD trial randomized patients with OAC or gastric cancer to groups that received perioperative chemotherapy or surgery alone, and demonstrated almost identi cal improvements in 5year overall survival in both groups 177, 178 . In addition, patients treated with docetaxel plus oxaliplatin and 5fluorouracil (known as the FLOT regimen) showed better pathological response rates than those treated with ECX in the FLOT4AIO RCT for localized gastric cancers, including OAC. The sur vival results from this study have been presented in the form of a conference abstract and demonstrate superior survival among patients treated with the FLOT regimen relative to those treated with ECX (50 months versus 37 months; hazard ratio (HR): 0.77 (95% CI: 0.63-0.94); P = 0.012) 179, 180 . Metaanalyses support the consistency of these findings, and it is recommended that patients with OAC are treated with either neoadjuvant or peri operative platinumbased and fluoropyrimidinebased chemotherapy (including an adjuvant component, if tolerated) 6, 7, 181 .
Neoadjuvant chemoradiotherapy.
Chemoradio therapy is also an effective preoperative treatment for OSCC and OAC, but especially for OSCC (TABLE 3) . However, in patients with very earlystage cancers, neoadjuvant chemoradiotherapy does not lead to a survival advantage when compared with surgery alone 182 . Radiotherapy for patients with oesophageal cancer should be planned using CT simulation and conformal treatment planning 7 . Intensitymodulated radiation therapy may be used if dose reductions to specific organs cannot be achieved using standard 3D planning mechanisms 7 . A comparison of weekly carboplatin and paclitaxel in addition to radiotherapy (known as the CROSS regi men) versus surgery alone in the CROSS trial 183 showed that neoadjuvant chemoradiotherapy resulted in improved overall survival for all patients, although the magnitude of this benefit was greater for patients with OSCC than for patients with OAC (HR: 0.453 (95% CI: 0.243-0.844) versus 0.732 (95% CI: 0.524-0.998) for OSCC and OAC, respectively). These results have led to the widespread adoption of the CROSS regi men as a standard treatment option for oesophageal cancer, especially for OSCC, thus replacing older and more toxic regimens, although there are some concerns 184 . Notably, patients with lymph nodepositive cancers did not seem to derive the same magnitude of sur vival benefit following subgroup analysis. Concerns regarding the adequacy of the systemic dose of chemo therapy in the CROSS regimen are mitigated by a clear decrease in the occurrence of distant metastases in patients treated with chemotherapy (HR: 0.63 (95% CI: 0.46-0.87)), albeit only for the first 2 years following surgical resection 185 . A comparison of chemoradiotherapy versus chemo therapy has only been done in one small study showing equivalent survival outcomes 186 . However, several large randomized phase III trials are currently evalu ating chemoradiotherapy versus chemo therapy. The findings will be of particular interest in view of the improved sur vival results recently presented for perioperative FLOT chemotherapy, which are equiv alent to those demonstrated in the CROSS trial for chemoradiotherapy 186 .
Combining induction chemotherapy to reduce dis tant metastases with chemoradiotherapy that improves local control would seem to be an attractive option. How ever, the role of induction chemotherapy before neo adjuvant chemoradiotherapy has not yet been confirmed, and results from small RCTs are inconsistent 187, 188 .
Definitive chemoradiotherapy. Definitive chemoradio therapy is recommended for cervical OSCC tumours, and can be considered as an alternative standard of care for OSCC of the mid and lower oesophagus 6, 7 . Compared with chemoradiotherapy followed by sur gery, definitive chemoradiotherapy has been associated with an equivalent survival of patients with OSCC but higher rates of local relapse in two RCTs 172, 173 . The standard dose of radiotherapy in definitive protocols is 50.4 Gy, despite recent technical developments in radiotherapy delivery; the use of doseescalated radio therapy has not yet been validated in RCTs 189 . If salvage oesophagectomy is considered as a therapeutic strategy, doses higher than 55 Gy should be avoided because they are linked with increased postoperative mortality and morbidity 190 . However, as local relapse rates are substantial, sur gery might still be required following defin itive chemo radio therapy. There are no data that compare prospectively whether salvage surgery upon relapse following chemo radiotherapy is superior to neoadjuvant chemoradio therapy followed by surgery; ongoing clinical trials are investigating this question. In the past, salvage oesophagectomy was associated with a higher rate of postoperative complications (for example, anastomotic leak rate) than was planned oesophagectomy, but the use of riskreduction approaches -such as omental transposition and anastomosis outside the irradiated oesophagus -during salvage oesophagectomy in highvolume centres may reduce this risk so that it is equivalent to that of a planned surgery 191, 192 . Definitive chemoradiotherapy is also an option for patients with OAC who are unsuitable for or who refuse surgery, but it is not the standard approach. In defini tive chemoradiotherapy, cisplatinbased, oxaliplatin based or fluoropyrimidinebased regimens have equivalent efficacy 193 .
Palliative treatment
As many oesophageal cancers are unresectable at diag nosis, and more than half of patients who are treated with curative intent will develop tumour recurrence, the majority of patients will ultimately require palli ative therapy 174, 176 . Radiotherapy or stent placement might reduce the symptoms associated with the pri mary tumour, but palliative chemotherapy is required for systemic disease control. Few studies have evaluated the role of palliative chemotherapy solely in oesopha geal cancer, and therefore data are frequently extrapo lated from trials containing a mixture of oesophageal, junctional and stomach cancers. In addition, studies assessing palliative chemotherapy in OSCC versus OAC are needed 194, 195 . Palliative chemotherapy for oesophageal cancer is predominantly platinumbased and fluoropyrimidine based 6, [196] [197] [198] . On the basis of the results of the REAL2 trial, oxaliplatin and cisplatin are considered to be equivalent in terms of efficacy, but not in terms of their toxicity profiles; oxaliplatin was associated with increased rates of neuropathy and diarrhoea, and cis platin with thromboembolic events and neutropenia 199 . Capecitabine has replaced infused 5fluorouracil in many chemotherapy regimens as it does not require a central venous access device, but infused 5 fluorouracil plus oxaliplatin (FOLFOX) remains a popular regi men. In Asia, S1 (containing tegafur, gimeracil and oteracil) is a standard treatment for advanced gastro oesophageal cancer in combination with cisplatin, but the pharmaco genomics affecting the tolerability of this regimen in nonAsian populations have limited the use of S1 outside of Asia 200, 201 . Patients with oesophageal cancer who progress on firstline therapy may benefit from secondline chemotherapy, such as taxanes and irinotecan. However, the median overall survival bene fit associated with secondline cytotoxic chemotherapy relative to that associated with the best supportive care is approximately 6 weeks [202] [203] [204] . As the median overall survival in clinical trials for patients treated with palliative chemotherapy for gastro oesophageal cancer is <1 year 199 , a consideration of the toxicitytoefficacy ratio is required when selecting a regimen. Chemotherapy increases overall survival rela tive to the best supportive care (HR: 0.37 (95% CI: 0.24-0.55)) 205 . A Cochrane metaanalysis showed that triplet chemotherapy is superior to doublet chemo therapy 205 . However, although standard triplet regimens improve survival, they have increased toxicity, and care ful patient selection or modification of these regimens is recommended 206, 207 .
Overexpression or amplification of HER2 is common in OAC (it is found in 30% of OAC tumours in TCGA and 32.2% of gastrooesophageal junction tumours in the ToGA screening cohort) 4, 208 . Patients with oesopha geal tumours that overexpress HER2 are usually treated with the antiHER2 monoclonal antibody trastuzumab in combination with cisplatin plus fluoropyrimidine chemotherapy, and this was demonstrated to improve overall survival in the ToGA trial for HER2positive gastric and gastrooesophageal junction cancer 6, 7, 209 . As OAC has recently been shown to be molecularly very similar to chromosomally unstable gastric adeno carcinoma 4 , antiHER2 therapy in OAC has a strong biological rationale. The antivascular endothelial growth factor receptor 2 (VEGFR2) mono clonal anti body ramucirumab also improves overall survival both as a single agent (median overall survival: 3.8 months versus 5.2 months for the best supportive care ver sus ramucirumab) and in conjunction with paclitaxel (median overall survival: 7.4 months versus 9.6 months for pacli taxel versus paclitaxel plus ramucirumab), but it has only been evaluated in gastric and gastro oesophageal junctional adenocarcinoma, although based on TCGA results, this is clearly a continuum with OAC 4, 210, 211 .
Quality of life
The QOL of patients with oesophageal cancer is first negatively affected by the symptoms that are associated with the obstructing tumour and later by the adverse effects of treatment. Measurements of QOL after con firmation of the diagnosis but prior to treatment are often used as 'baseline' . Such measurements can be valuable for the adjustment of differences between groups in statis tical analyses, but they do not mirror the actual baseline level because most patients at that point in time are already seriously affected by their disease. Before diagnosis, the majority of individuals with oesophageal cancer experi ence dysphagia, eating difficulties and appetite loss, resulting in considerable weight loss and fatigue, which influence the daily life and QOL of patients 13 . Individuals who have advancedstage tumours may suffer from additional problems -such as odynophagia, hoarseness and coughing -owing to tumour overgrowth or metastatic disease 212 . Good communication between health care profes sionals and patients facilitates adjustment to illness and improves QOL. In conjunction with information about different treatments and their influence on QOL, patients often require information about the potential longterm benefits and consequences of treatments, including topics such as work ability, social function ing and physical symptoms. A core information set with aspects that should be discussed with patients before treatment has been developed. This set includes information on what to expect upon admission, dur ing hospital stays (for example, information about major complications), and after treatment and dis charge (for example, expected recovery milestones, and the effect of treatment on eating, longterm QOL and survival) 213 .
To prepare for curative treatment, preoperative inter ventions that improve patient survival and treatment success rate are being studied 214, 215 . As malnourished patients are at a greater risk of surgical morbidity and mortality, attention to preoperative nutritional status is needed 216 . If intervention for feeding is required because of dysphagia, jejunostomy is preferred to stenting in operable cancer 217 . Neoadjuvant therapy reduces physi cal fitness and social functioning, and increases fatigue, nausea and vomiting, dyspnoea, appetite loss, diarrhoea and taste problems during treatment, but recovery is usually achieved before surgery, and postoperative recovery is similar to that of patients receiving surgery alone 218 . Few studies have evaluated the influence of definitive chemoradiotherapy on the QOL of patients. A multicentre RCT showed that definitive chemoradio therapy negatively affects the QOL of patients during treatment, but the symptoms are usually resolved within 6 months, except for persisting fatigue and insomnia 219 .
Patients undergoing definitive chemoradiotherapy tend to recover faster than those who undergo surgery 219 . Oesophagectomy has a detrimental effect on the QOL of patients in the short term and the long term. Complications after surgery are the strongest known risk factor for poor QOL, and for delayed and incom plete recovery 220, 221 . After surgery, most patients struggle with loss of appetite, difficulty eating, and severe and longstanding postoperative weight loss, and thus the support of a dietician is warranted 13, 222 . The majority of patients are not eligible for curative treatment and will thus undergo palliative treatment, which has the main aim of prolonging survival while preserving QOL. The literature assessing QOL in patients undergoing palli ative treatment is limited, but this is an important area for future research 223 . Clinical guidelines do not provide much informa tion on how patients with oesophageal cancer should be followed up after treatment regarding, for example, the frequency or duration of followup. One important aim of the followup is to support patients in their recov ery after treatment. Supportive care needs after treat ment may differ substantially between patients, and a tailored followup supported by a multidisciplinary team is recommended. With the increasing incidence of OAC, combined with improvements in survival, more patients will need longterm followup. To meet the burden on the outpatient clinic, nurseled follow ups have been evaluated, and studies have reported encouraging results regarding patient satisfaction and costeffectiveness [224] [225] [226] .
Outlook
As multiplatform molecular characterization studies examining oesophageal cancer continue to accumu late, it is likely that the findings of this research will begin to have an effect on the future diagnosis and individualized management of this disease, and that the treatments for OSCC and OAC may further diverge 4 . Earlier diagnosis in larger numbers of care fully selected highrisk patients might be facilitated by the use of noninvasive methods to obtain samples (such as Cytosponge or the assessment of volatile organic solvents in exhaled breath) and by the opti mization of biomarkers specific for dysplasia and early cancer 227 . This approach should lead to the increased use of curative endoscopic therapy and a reduction in oesophagectomies.
For patients with locally advanced cancers who require neoadjuvant chemotherapy or chemoradio therapy, ongoing clinical trials will address several important questions. These questions include whether neoadjuvant chemotherapy, chemoradiotherapy or induction chemotherapy followed by chemoradio therapy is the ideal treatment for resectable OAC, and when (if any) the best time to perform oesophagectomy following chemoradiotherapy for OSCC is.
In addition, several new therapies or treatment targets have been tested for the management of oesopha geal cancer, and several promising studies are ongoing. The development of targeted therapies in oesophageal cancer over the past decade has been disappointing, with the exception of trastuzumab. International RCTs have investigated agents that target EGFR, the tyro sineprotein kinase MET (also known as hepatocyte growth factor receptor), mechanistic target of rapa mycin (mTOR), and the VEGF and FGFR pathways without success [8] [9] [10] [11] [228] [229] [230] [231] . The unmet need for trials in OSCC is highlighted by the fact that only one of these studies (the COG trial 228 ) enrolled patients with OSCC. For OAC, the challenges associated with biomarker selection and targeted therapy are exemplified by HER2 expression, for which clear evidence of significant intra patient heterogeneity of HER2 and the deleterious effect of heterogeneity on the response to antiHER2 therapy has accumulated [232] [233] [234] . The role of gene copy load, intra tumoral heterogeneity and receptor tyro sine kinase coamplification on the response to targeted therapy has also been demonstrated for EGFRamplified, FGFR amplified and METamplified gastro oesophageal tumours 85, 235, 236 . As the amplification of receptor tyro sine kinases is one of the key targetable lesions in OAC (and in chromosomally instable gastric cancer), the identification of patients in whom the tumour is truly dependent on receptor tyrosine kinase signalling and who are most likely to benefit from drugs that target these pathways is an important future challenge.
Prospective pathways that could be investigated as the targets of targeted therapy in oesophageal cancer include cell cycle regulators and the DNA damage response pathway. Cell cycle pathway dysregulation is present in up to 90% of OSCC tumours and 86% of OAC tumours via distinct but overlapping mech anisms 4 ( FIG. 7; TABLE 2 ). Inhibitors of CDK4 and CDK6 -such as ribociclib and palbociclib -which have been shown to improve survival in oestrogen receptorpositive breast cancer 237 , could be used in OAC tumours that have CDK4 and CDK6 amplifications; these tumours have been shown to depend on CDK4 and CDK6 sig nalling in pre clinical studies 238 . The development of drugs such as PARP inhibitors, which target the DNA damage response pathway, in gastro oesophageal cancer has also been hindered by the absence of biomarkers for population selection 239 . However, moving beyond immunohistochemistry biomarkers associated with an impaired DNA damage response to morenuanced sig natures using nextgeneration sequencing -like those used to predict response to PARP inhibition in ovarian cancer -may be useful in the future 84, 240, 241 . Oesophageal cancer is associated with a relatively high mutational load, which, in other tumours, is corre lated with response to therapy directed at programmed cell death protein 1 (PD1) 80, 242 . Data on the use of antiPD1 therapy in oesophageal cancer are prelim in ary but encouraging. The objective response rate of 23 patients who had PD1 ligand 1 (PDL1)positive oesopha geal cancer and were treated with pembroli zumab in the phase Ib KEYNOTE028 study was 30% overall (40% for OAC and 29% for OSCC) 243 . A PDL1unselected population of 64 patients with OSCC demonstrated an independently reviewed objec tive response rate of 17% to nivolumab (an antiPD1 anti body) therapy 244 . Patients with PDL1unselected gastric or gastro oesophageal junctional adenocarcinoma were treated with nivolumab or nivolumab plus ipilimumab (an antibody that targets cytotoxic T lympho cyte pro tein 4 (CTLA4)) in the CHECKMATE 032 study 245 . Nivolumab treatment induced radiological responses in PDL1positive and PDL1negative tumours (27% versus 12% for PDL1 levels of ≥1% and <1%, respec tively), and these responses were more frequent in both PDL1negative and PDL1positive patients who were treated with combination immunotherapy 245 . A phase III RCT has demonstrated the superiority of nivolumab in terms of overall survival relative to the best supportive care in patients with chemorefractory gastric cancer, with a key finding of an improvement of 1year survival from 10% to 26% in nivolumabtreated patients despite a relatively low radiological response rate of 11% 246 . Thus, it is likely that, pending the results of ongoing trials, checkpoint inhibitor therapy with agents such as nivolumab and ipilimumab will be integrated into treatment paradigms for patients with oesophageal cancer 246 . Given the rapid development of immunooncology therapies and the promising preliminary results, other questions arise, such as how best to select patients for immunooncology therapy and how to integrate these treatments into other molecularly targeted and cur rent treatment paradigms. Together, these advances in screening, diagnosis and treatment may have the pos itive impact of reducing the morbidity and mortality associated with oesophageal cancer. Drugs shown in red have been tested in patients with oesophageal cancer, without success. Drugs highlighted in yellow are currently being evaluated or could be evaluated on the basis of emerging data on active pathways in oesophageal cancer. Regorafenib, apatinib and nivolumab have improved the overall survival of patients with gastric cancer in randomized trials. At the time of publication, the only drugs that have achieved a survival advantage in patients with oesophageal cancer in randomized trials with a control group are trastuzumab and ramucirumab (green). CDK, cyclin-dependent kinase; CTLA4, cytotoxic T lymphocyte protein 4; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; FGFR, fibroblast growth factor receptor; HDAC, histone deacetylase; HER2, human epidermal growth factor receptor 2; MEK, MAPK/ERK kinase; MMP9, matrix metalloproteinase 9; mTOR, mechanistic target of rapamycin; PD1, programmed cell death protein 1; PDL1, PD1 ligand 1; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homologue; STAT3, signal transducer and activator of transcription 3; VEGFR, vascular endothelial growth factor receptor.
